A Torrance company is hoping to help people with sickle cell disease with a new treatment.
Emmaus Life Sciences will have their new treatment, Endari, evaluated by the Federal Drug Administration’s Oncologic Drugs Advisory Committee tomorrow. So far, there hasn’t been a new treatment approved for patients with sickle cell disease in almost 20 years, and there are currently no approved treatments for pediatric patients.
Endari can be used for adults and children. It is an oral, daily maintenance treatment.
Patients with sickle cell disease suffer from episodes of excruciating pain and have a shortened life expectancy. It affects 100,000 patients in the United States. The current standard of care is hydroxyurea, a chemotherapy agent for use in adults with at least three painful crisis in the previous year, which can have adverse effects.